Please provide your email address to receive an email when new articles are posted on . Platysma prominence treatment with 26 to 36 units of onabotulinumtoxinA was well-tolerated and had a favorable ...
In both phase 3 trials, onabotulinumtoxinA significantly improved platysma band severity at maximum contraction compared with placebo. The Food and Drug Administration (FDA) has approved Botox ® ...
(RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced that FDA approves BOTOX® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the ...
IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance ...
The FDA warning letters mostly went to cosmetic websites. In each case, the FDA said the companies were offering unofficial ...